08.01.2018 15:00:00
|
ResMed Announces Its Premier Portable Oxygen Concentrator, Mobi
SAN FRANCISCO, Jan. 8, 2018 /PRNewswire/ -- ResMed (NYSE: RMD, ASX: RMD) today introduced Mobi, its first ResMed-branded portable oxygen concentrator (POC).
Mobi offers an industry-leading balance of oxygen delivery, weight and battery life so that millions with chronic obstructive pulmonary disease (COPD) or other respiratory condition can enjoy ResMed-quality oxygen therapy at home or on the go.
"We have focused decades of patient-centered ResMed technology and design innovation into this POC," said ResMed CEO Mick Farrell. "We've achieved great mobility, comfort and therapy quality in sleep apnea treatment with AirMini, the world's smallest PAP device. Mobi offers that same great balance to the many millions of people who rely on supplemental oxygen to enjoy their highest quality of life."
Mobility is particularly key for oxygen patients with chronic obstructive pulmonary disease. Regular physical activity is shown to lower the risk of hospitalization and death among those with COPD, according to a 2006 study published in Thorax: http://thorax.bmj.com/content/61/9/772.
"The time is now for portable oxygen," said Farrell. "Our patients demand a device that enables them to get out of their house and travel to visit friends and family. Mobi gives the gift of freedom to millions."
Availability
Mobi will be available to U.S. patients through their home medical equipment (HME) providers later this quarter. ResMed is pursuing clearance to sell in other countries in 2018.
About ResMed
ResMed (NYSE: RMD, ASX: RMD), a world-leading connected health company with more than 4 million cloud-connected devices for daily remote patient monitoring, changes lives with every breath. Its award-winning devices and software solutions help treat and manage sleep apnea, chronic obstructive pulmonary disease and other respiratory conditions. Its 6,000-member team strives to improve patients' quality of life, reduce the impact of chronic disease and save healthcare costs in more than 120 countries. ResMed.com
For media: | For investors: |
Jayme Rubenstein | Agnes Lee |
+1 858-836-6798 | +1 858-836-5971 |
View original content with multimedia:http://www.prnewswire.com/news-releases/resmed-announces-its-premier-portable-oxygen-concentrator-mobi-300578384.html
SOURCE ResMed Inc.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu ResMed Inc.mehr Nachrichten
21.02.25 |
S&P 500-Titel ResMed-Aktie: So viel Gewinn hätte ein Investment in ResMed von vor 10 Jahren eingefahren (finanzen.at) | |
07.02.25 |
S&P 500-Wert ResMed-Aktie: Hätte sich eine Investition in ResMed von vor 3 Jahren rentiert? (finanzen.at) | |
31.01.25 |
Börse New York in Rot: S&P 500 notiert letztendlich im Minus (finanzen.at) | |
31.01.25 |
Börse New York in Grün: S&P 500 verbucht am Freitagnachmittag Gewinne (finanzen.at) | |
31.01.25 |
Börse New York in Grün: S&P 500 mit positivem Vorzeichen (finanzen.at) | |
31.01.25 |
Zuversicht in New York: S&P 500-Anleger greifen zum Start des Freitagshandels zu (finanzen.at) | |
31.01.25 |
S&P 500-Wert ResMed-Aktie: So viel hätte eine Investition in ResMed von vor einem Jahr abgeworfen (finanzen.at) | |
29.01.25 |
Ausblick: ResMed öffnet die Bücher zum abgelaufenen Quartal (finanzen.net) |
Analysen zu ResMed Inc.mehr Analysen
Aktien in diesem Artikel
ResMed Inc. | 218,80 | -2,19% |
|